(Bloomberg) -- Novavax ... vaccine at its own cost. Shares of Sanofi rose slightly in early trading in Paris. The stock was down about 5% in the past 12 months through Thursday’s close. The deal ...
Novavax has secured a transformative partnership with Sanofi, which includes $1.2 billion in potential payments and critical commercial support. The company’s COVID-19 vaccine targets the JN.
Sanofi has licensed joint commercial rights to Novavax’s COVID-19 vaccine and will work with the biotech on the development of combined flu/COVID shots in a deal worth up to $1.2 billion.
Per the deal terms, Sanofi took a minority stake in NVAX (a $70 million equity investment), will gain rights to co-market Novavax’s COVID-19 vaccine globally, and will have the sole license to ...
The top-three investor in Novavax ... malaria vaccine – which uses its Matrix-M adjuvant – had been shipped by partner Serum Institute of India to Africa. The deal with Sanofi includes ...
Gaithersburg, Maryland-based Novavax received ... it struck a $1.2 billion licensing agreement with French drugmaker Sanofi to co-commercialize the combination vaccine. Get breaking news and ...
PR Newswire • 16 days ago Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized ... Welcomes Recent Announcement by Novavax of Licensing Agreement with Sanofi Stresses Significant Value ...
Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the stock offers the best reward prospects in the industry. Novavax stock ...
Novavax (NASDAQ:NVAX), Sanofi (NASDAQ:SNY) – Novavax closed a $1.4 billion deal with Sanofi to commercialize its Covid-19 vaccine and ... it aims to close data licensing deals and explore ...